Predict your next investment

Private Equity
medicavp.com

See what CB Insights has to offer

Investments

39

Portfolio Exits

10

Funds

3

About Medica Partners

Medica Partners has pioneered healthcare investing in Israel beginning in 1995 and has provided investment capital to support companies developing breakthrough products including first and second generation percutaneous heart valves. With experience in all stages of company formation and growth, Medica recognizes the 'diamond in the rough' which less experienced investors ignore.

Medica Partners Headquarter Location

4 HaSadnaot St. Kohav Herzliya Bldg.

Herzliya, 46728,

Israel

+972 (9) 960-1900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Medica Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Medica Partners in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Medica Partners News

Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID19

Mar 5, 2020

Renowned Chinese medical research institution in Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences, enters a strategic collaboration with Canadian-based biotechnology company Cyclica to discover antiviral drug candidates for COVID-19 and explore opportunities to design multi-targeted antiviral compounds. While current efforts to develop new medicines through generative approaches for the COVID-19 outbreak can result in possible therapies, new drug development efforts can be resource intensive and require a number of years of both pre-clinical and clinical testing. As such, drug repurposing offers a more effective strategy that suits the urgency of the need for treatments of COVID-19. Artificial intelligence (AI) approaches to drug repurposing can be deployed to further expedite the recommendation of potential therapeutic solutions. Cyclica used its proprietary deep learning engine, MatchMakerTM, to screen a collection of more than 6,700 FDA-approved drugs and drug candidates with at least Phase I clinical data against the structurally-characterized human proteome. MatchMaker is trained on millions of known human drug-target interactions (DTI) in addition to structural data. The resulting first-in-class database, named PolypharmDB, is a library of clinically assessed molecules and their polypharmacological profiles that can be used to identify repurposing opportunities for drug candidates. Leveraging PolypharmDB and MatchMaker, Cyclica's scientists investigated both human targets as well as viral proteins with potential therapeutic relevance for COVID-19 in rapid fashion. The result is a set of molecules that are predicted to interact with the putative therapeutic targets for COVID-19. While the results are promising, modelling viral proteins pushes MatchMaker beyond established benchmarks, increasing the uncertainty around predictions for those targets. The prioritized set of molecules resulting from the interrogation of PolypharmDB represents an actionable collection of molecules primed for testing. In this collaboration, China’s Institute of Materia Medica will conduct in vitro and in vivo antiviral assessment for molecules proposed by Cyclica. In addition, the two parties will cooperate in a longer-term effort to design multi-target antiviral compounds with the goal of reducing drug resistance. This international partnership is built on a historical relationship between Cyclica and China that stemmed from China-Canada Angel Alliance (CCAA), an angel investment group registered in Ontario, Canada. Naheed Kurji, President & CEO of Cyclica, says, "We have been closely following the progression of COVID-19 epidemic in China, and increasingly around the world. At the same time, we want to contribute our AI platform to searching for innovative therapies to overcome this viral outbreak in a way that is conducive to a rapid response. The opportunity to work with the leading scientists at the Institute of Materia Medica, Chinese Academy of Medical Sciences is one that we couldn’t pass up." About China’s Institute of Materia Medica The Institute of Materia Medica (IMM) was founded in 1958. Its scientists use the latest biomedical theories, cutting-edge technologies, and state-of-the-art laboratory equipment to develop drugs from botanical compounds, synthetic chemicals, and bioproducts. Since the institute’s establishment, its scientists have discovered or developed hundreds of new drugs and acquired 130 new drug certificates from the China Food and Drug Administration, IMM’s contributors have won 230 awards from the government and professional societies for drug research and development. About China-Canada Angel Alliance China-Canada Angel Alliance (CCAA) is an angel investment agency registered in Ontario, Canada, established in 2014 by a group of angel investors from Zhongguancun River Capital and the Zhongguancun Angel 100. CCAA is committed to building a cross-border ecosystem between China and Canada, and promoting international exchanges and collaboration between Chinese and Canadian entrepreneurs through joint investment, entrepreneurial mentorship, and connecting cross-border resources. About Cyclica, Inc Cyclica is a Toronto, Canada based biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. Cyclica’s differentiated platform opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing for a wide range of indications. With a world-class team with deep roots in industry and a first-in-class integrated drug discovery platform, Cyclica will spark a surge of innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies. By doing more with AI, Cyclica will revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision. View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005764/en/ Davesh Chauhan

Medica Partners Investments

39 Investments

Medica Partners has made 39 investments. Their latest investment was in Regentis Biomaterials as part of their Series D on February 2, 2016.

CBI Logo

Medica Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/7/2016

Series D

Regentis Biomaterials

$15M

No

Generali Investment, Haisco Pharmaceutical Group, SCP Vitalife, and Technion Research & Development Foundation

4

7/21/2015

Series B - III

Avaxia Biologics

$1.01M

No

AbbVie Biotech Ventures, Cherrystone Angel Group, and Golden Seeds

1

6/25/2015

Seed VC - II

Christcot Medical Company

$3.2M

No

1

5/6/2014

Debt

Subscribe to see more

$99M

Subscribe to see more

10

3/12/2014

Convertible Note - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/7/2016

7/21/2015

6/25/2015

5/6/2014

3/12/2014

Round

Series D

Series B - III

Seed VC - II

Debt

Convertible Note - II

Company

Regentis Biomaterials

Avaxia Biologics

Christcot Medical Company

Subscribe to see more

Subscribe to see more

Amount

$15M

$1.01M

$3.2M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Generali Investment, Haisco Pharmaceutical Group, SCP Vitalife, and Technion Research & Development Foundation

AbbVie Biotech Ventures, Cherrystone Angel Group, and Golden Seeds

Sources

4

1

1

10

10

Medica Partners Portfolio Exits

10 Portfolio Exits

Medica Partners has 10 portfolio exits. Their latest portfolio exit was PainReform on September 09, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/9/2020

IPO

$991

1

2/1/2018

IPO

$991

3

7/2/2014

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

9/9/2020

2/1/2018

7/2/2014

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Medica Partners Fund History

3 Fund Histories

Medica Partners has 3 funds, including Medica III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2006

Medica III

Early-Stage Venture Capital

$115M

1

12/31/2000

Medica II

Subscribe to see more

$99M

10

1/31/1995

Medica I

Subscribe to see more

$99M

10

Closing Date

12/31/2006

12/31/2000

1/31/1995

Fund

Medica III

Medica II

Medica I

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$115M

$99M

$99M

Sources

1

10

10

Medica Partners Team

7 Team Members

Medica Partners has 7 team members, including current Chief Financial Officer, Yoav Waizer.

Name

Work History

Title

Status

Yuval Binur

Founder

Current

Ehud Geller

Founder

Current

Yoav Waizer

Chief Financial Officer

Current

Batsheva Elran

Managing Partner

Current

Eli Hazum

General Partner

Current

Name

Yuval Binur

Ehud Geller

Yoav Waizer

Batsheva Elran

Eli Hazum

Work History

Title

Founder

Founder

Chief Financial Officer

Managing Partner

General Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.